This research will be presented at the Society for Immunotherapy of Cancer (SITC 2022) 37 th Annual Meeting, November 8-12, in Boston, Massachusetts. Repertoire Immune Medicines may also be known as or be related to Repertoire Immune Medicines and Repertoire Immune Medicines Inc.Research from Repertoire’s DECODE Platform Provides Detailed Characterization of the Immune Synapse Response in HPV 16 and HPV 33 Positive Oropharyngeal Squamous Cell Carcinoma Including Epitopes Driving Cytotoxic Responseĭata to be presented at the Society for Immunotherapy of Cancer 37 TH Annual MeetingĬAMBRIDGE, Mass., October 05, 2022-( BUSINESS WIRE)- Repertoire® Immune Medicines will present data from its ongoing research to characterize the cellular response and identify novel therapeutic targets with the company’s DECODE™ platform in human papillomavirus (HPV) 16 and HPV 33 positive tumors. The data presented on this page does not represent the view of Repertoire Immune Medicines and its employees or that of Zippia. None of the information on this page has been provided or approved by Repertoire Immune Medicines. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies.

The employee data is based on information from people who have self-reported their past or current employments at Repertoire Immune Medicines. Zippia gives an in-depth look into the details of Repertoire Immune Medicines, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Repertoire Immune Medicines.

John received a PhD in Physiology from the University at Buffalo and an MBA from Maryville University of Saint Louis. Earlier in his career he had business development roles at Kalypsys and R&D and business development roles at Pharmacia. Before he joined Tmunity he was the Executive Director of Business Development and Licensing at Merck, and prior to this role he was at Novartis where he was a member of the Novartis Institutes for BioMedical Research business development leadership team and led the search and evaluation group. In this role John led business development and contributed to the development of the overall corporate strategy. John was most recently at Tmunity Therapeutics, a T cell, solid tumor therapeutics company where he served as VP, Corporate Development. At Repertoire, John leads the corporate and business development function. John joined Repertoire with more than 20 years of business and corporate development leadership experience at both small and large biotechnology and pharmaceutical companies.

Repertoire immune medicines